Every letter we have printed

You say no dose-equivalence data exists between agents in this class. During the shortage my pharmacy substituted one for another on the basis of a conversion table they had printed from somewhere. Where would such a table have come from?

The framing of maintenance as a lower-effort phase may be the single most misleading idea in the popular coverage. Everything in the published follow-up data suggests the opposite, and the framing survives because it is the one people want to hear.

Your dossier work has shown that suppliers will supply what is asked for individually. That is the strongest evidence that the constraint is demand rather than capability, and it is the more hopeful finding.

I priced a sterility and endotoxin package for a small batch last year and the cost per surviving vial was substantial but not prohibitive. The obstacle was not money. It was that no supplier I approached had a route to commission it, and none of them had ever been asked.

Speaking as somebody who has signed a good many of these: the signature is not a formality to the person signing it. It is the reason I have refused to release a report on a run whose suitability data I did not like, and the reason I would refuse again. The document is one of the few places in this trade where an individual is on the record.

Buyers could create accountability tomorrow by asking for it. A purchase order that makes the certificate a term of the contract changes the position entirely, and it takes one sentence. The absence is a habit rather than a barrier.

The lot number should appear in a form that can be matched to the vial without interpretation. Half the certificates I hold carry a batch code with a different number of digits from the one printed on the label, and reconciling them is guesswork the buyer should not be doing.

The most useful sentence in the piece is the one saying a bad document is not a bad product. I have spent two years on forums watching people conclude the opposite from a missing signature block, and it has made the whole conversation about honesty rather than about paperwork.

The monoisotopic against average distinction is the one I spend most time explaining. Below about two kilodaltons the monoisotopic peak is the one you can see and the one you should quote. Above it the isotope envelope broadens until the average is the honest description, and a certificate quoting a monoisotopic mass for a large peptide is quoting a peak nobody resolved.

A small point on units. Parts per million mass accuracy is a proportion, so five parts per million on a small peptide is a few thousandths of a dalton and on a large one is rather more. Quoting an accuracy specification without the mass it applies to is the same error your chromatography pieces complain about.

Tandem mass spectrometry with sequence coverage stated as a percentage is the thing to ask for, and the percentage is the part that gets omitted. Sixty per cent coverage on a thirty-residue peptide leaves twelve residues unverified, and where those twelve sit determines whether the result means anything.

A small defence of the linear MALDI instrument. It is fast, it tolerates dirty samples, and for a synthesis chemist checking that a chain has grown by the residue intended it is entirely fit for purpose. The problem is not the instrument. It is printing its output on a release document.

Interval and half-life are related by arithmetic that is published for each compound in this class, and the discussion proceeds mostly without it. The accumulation ratio for a given interval is calculable and rarely calculated.

A step from one dose to the next is a proportional change and the proportion shrinks as the doses rise. Doubling early in a schedule is a much larger relative change than the same absolute increment later, and tolerability tracks the proportion rather than the milligrams.

Protein intake is recorded in some of these trials by food diary, which has a well-characterised and large reporting error. Any analysis conditioning on that variable is conditioning on a noisy estimate and should say so.

Distribution across the day has a modest evidence base and it is a great deal weaker than the total. Presenting the two as equally established is a common error in popular summaries and it displaces attention from the number that matters.

Where a study reported no benefit from an activity component, the usual explanation offered is adherence rather than efficacy, and adherence was measured by self-report. That explanation may be right and it is not supported by the data used to make it.

Trials that included a structured activity component and trials that did not are compared directly in most coverage, and the component is one of the largest determinants of the composition outcome. It should be the first thing in any comparison table.

A brief thank you from a reader who works well outside this field and follows it anyway. The writing assumes intelligence without assuming background, which is harder than it looks.

Duration is the open question underneath all of this. If the honest answer is that nobody knows how long is appropriate, that should be the sentence rather than a set of conventions presented as guidance.

The distinction between maintaining a result and maintaining a dose is collapsed everywhere. They are separable questions and the published data addresses the second far better than the first.

Stopping without telling anybody is common and it makes the observational data worse than it looks, because somebody recorded as continuing may have stopped months earlier. Persistence measured from prescription records and persistence in fact are different quantities.

The reasons literature would improve enormously if a single study published the free-text answers alongside the coded ones. The coding is where the information is lost, and the raw text usually still exists.

Your fortnightly arithmetic table is correct but I think it understates the practical point. A fourfold peak-to-trough swing is not merely lower average exposure; it is a different drug experience, with the last few days of each cycle spent at a concentration the person has effectively titrated off.

Where custody is genuinely maintained, the cost is not in the paperwork but in the handling: dedicated packaging, tracked transfer, a named recipient at each end. It is perfectly achievable and it roughly doubles the price of a determination.

A practical point about labelling for submission. Write the identifier on the tube, not on a sticker, and not on the bag. Stickers come off in cold conditions and the laboratory then has a tube with no name and a bag with no contents.

Bioimpedance estimates total body water and infers the rest, which means that during rapid change it is estimating the quantity that is moving fastest and is least stable. Its precision is fine and its accuracy is a different matter, and the two get conflated constantly.

The smallest change an instrument can resolve is the number readers most need and are least often given. Below that threshold a difference between two scans is not a small change; it is not a change at all, and treating it as one drives a great deal of unnecessary anxiety.

Adherence is the variable that does most of the work and it is the one least often reported. A programme that is performed twice a week for a year beats a better programme abandoned in March, and the trial literature systematically studies the second kind.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

Regional and total measurements behave differently and are reported interchangeably. A total figure can be stable while a regional one moves substantially, and both are described as bone density.

You treat the column as a single value. In practice it is three: the stationary phase, the particle and pore dimensions, and the age of that particular column. The third is the one that moves results between two laboratories quoting the same part number, and no certificate has ever recorded it.

A short defence of long run times. Most of the disputes described in this series would be settled by adding fifteen minutes to the gradient and letting the late-eluting material come off inside the run rather than in the next injection. Throughput is the real reason methods are short, and throughput is a commercial value, not an analytical one.

Where a supplier does record temperature, ask for the file rather than the summary. A single maximum figure discards the duration, and duration above a threshold is what determines the loss.

The most useful thing a supplier can publish is its packing specification: pack type, quantity, insulation, and the tested hold time at a stated ambient. It is a page of text and it would let a buyer reason about their own climate.

The residual moisture in a lyophilised cake determines which pathways are available to it, and it is measurable, cheap and absent from most certificates in this trade.

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

A word of appreciation for the practice of quoting the sample size beside every figure. It has quietly deflated a good deal of what I used to believe.

Your description of gradient slope as the dominant variable matches our experience, but the way to express it is in per cent organic per column volume rather than per minute. Two laboratories running the same programme on different column dimensions are not running the same gradient, and the minute figure hides that.

Injection solvent belongs on your list. A sample dissolved in something stronger than the starting mobile phase will distort the leading peaks before the gradient has begun, and the distortion is worst for exactly the early-eluting impurities the method is meant to resolve. It costs nothing to state and almost nobody does.